Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation

Transplantation

Volumn 86, Issue 3, 2008, Pages 418-422

  Nair, Satheesh ^a,b   Lipscomb, Jeannie ^a   Eason, James ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hepatitis C; Interferon; Steroid free immunosuppression

Indexed keywords

AMANTADINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEGINTERFERON ALFA-2B;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIBROSIS; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; SEIZURE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; HEPATITIS C VIRUS; LIVER CIRRHOSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

AMANTADINE; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 52049116745     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817c1543     Document Type: Article

References (20)

1. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003; 9: 1129.
2. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666.
3. Nair S, Loss GE, Cohen AJ, et al. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81: 620.
4. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43.
5. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
6. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: anopen-label series. Transplantation 2004; 77: 190.
7. ChalasaniN, Manzarbeitia C,FerenciP,etal. Pegasys Transplant Study Group. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289.
8. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396.
9. Llado L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. J Hepatol 2006; 44: 710.
10. Bedossa P, Poynard T. METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis Cvirus infection.N EnglJMed2002; 347: 975.
13. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy onhepatitis Crecurrence after liver transplantation:arandomized controlled study. Gastroenterology 2007; 132: 1746.
14. Marcellin P, Jensen DM, Hadziyannis JS, et al. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (Pegasys) and ribavirin (Copegus). AASLD 2007, Oct. 2-6, Boston, MA [abtract#1308]. Hepatology 2007; 46(suppl): 818A.
15. Shiffman ML, Suter F, Bacon BR, et al.; ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for16 or 24weeksin HCV genotype 2 or 3. N Engl J Med 2007; 357: 124.
16. Mangia A, Minerva N, Annese M, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 989.
17. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630.
18. Ferenci P, Formann E, Laferl H, et al. Austrian Hepatitis Study Group. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatmentnaive patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44: 275.
19. Angelico M, Cepparulo M, Angelico F, et al. A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Aliment Pharmacol Ther 2004; 19: 339.
20. Bizollon T, Adham M, Pradat P, et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005; 79: 325.